At its Annual General Meeting on September 24, 2026, Standard Uranium shareholders approved all business items including setting the board size to five directors and re-electing Jon Bey, Blair Jordan, Kenneth Judge, Mike Young, and Douglas Engdahl. They also approved Davidson & Company LLP as auditor for the coming year and re-approved the company's Omnibus Plan. Additionally, the company granted 2.3 million incentive stock options and 4.05 million restricted share units to directors, officers, and consultants, with options exercisable at $0.08 until 2031. These moves support Standard Uranium’s ongoing exploration projects in the Athabasca Basin, a key uranium district in Canada, positioning the company for future growth and discovery.
Standard Uranium AGM results and compensation grants provide context for market activity. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 25, 2026 17:41 WIB: 23 of 38 US stocks rose, 14 fell. Notable movers include ICL at USD 5.32 (+2.61%), GFI at USD 40.87 (+2.43%), and PPG at USD 104.02 (-2.16%).
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
